 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Actavis (ACT) is a specialty pharmaceutical company, engages in developing, manufacturing, marketing, selling, and distributing generic, branded generic, brand, biosimilar, and over-the-counter pharmaceutical products worldwide.
The company offers its products for various therapeutic categories, such as cardiovascular, dermatology, urology, womens health, oncology, pregnancy prevention, hormones and synthetic substitutes, anti-infective agents, central nervous system, pain management, depression, hypertension, attention-deficit/hyperactivity disorder, and smoking cessation. It operates through three segments: Actavis Pharma, Actavis Specialty Brands, and Anda Distribution.
The Actavis Pharma segment develops, manufactures, and sells generic pharmaceutical products, as well as distributes generic versions of third parties brand products. This segment offers various dosage forms, such as oral solids, semi-solids, liquids, gels, transdermals, injectables, inhalation, and oral transmucosals. The Actavis Specialty Brands segment promotes and co-promotes Rapaflo, Gelnique, Crinone, Trelstar, Generess Fe, Androderm, Kadian, Crinone, AndroGel, INFeD, and sodium ferric gluconate branded products; and markets its products through sales professionals, as well as sells various non-promoted products.
The Anda Distribution segment distributes generic and selected brand pharmaceutical products, vaccines, injectables, and over-the-counter medicines to independent pharmacies, alternate care providers, pharmacy chains, and physicians offices. Actavis, Inc., sells its generic and brand pharmaceutical products primarily to drug wholesalers, retailers, and distributors; hospitals, clinics, mail order, and government agencies; and managed healthcare providers.
Shares have formed a bullish "flag" and higher share prices are expected for this stock.
52-Week Trading Range: $78.02 - $136.73
Entry Point: $135.62
Stop Loss: $129.00
Target Price: $149.40
We are closing ACT after its 30-day expired without reaching our 10% gain. We do, however, beleive this stock is heading higher and ACT is a solid company.
